{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:49:56Z","timestamp":1784195396538,"version":"3.55.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T00:00:00Z","timestamp":1417651200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114403","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T20:15:16Z","timestamp":1417724116000},"page":"e114403","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibiting Heat Shock Protein 90 (HSP90) Limits the Formation of Liver Cysts Induced by Conditional Deletion of Pkd1 in Mice"],"prefix":"10.1371","volume":"9","author":[{"given":"Zachary B.","family":"Smithline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Nikonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey H.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy Q.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Egleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Proia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamina","family":"Seeger-Nukpezah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Golemis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"VE Torres","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"VE Torres","year":"2009","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0002-9343(80)90266-1","article-title":"Liver cysts in patients with autosomal dominant polycystic kidney disease","volume":"68","author":"J Milutinovic","year":"1980","journal-title":"The American journal of medicine"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-2007-1007313","article-title":"Combined cystic disease of the liver and kidney","volume":"14","author":"ID D'Agata","year":"1994","journal-title":"Seminars in liver disease"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.V1191767","article-title":"Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma","volume":"11","author":"D Chauveau","year":"2000","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/hmg\/ddp588","article-title":"Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes","volume":"19","author":"A Kurbegovic","year":"2010","journal-title":"Human molecular genetics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/hep.23511","article-title":"Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice","volume":"51","author":"C Spirli","year":"2010","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2009.09.005","article-title":"ERK1\/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice","volume":"138","author":"C Spirli","year":"2010","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","author":"WE Sweeney Jr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"JM Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin slows progression of polycystic kidney disease","volume":"23","author":"JM Shillingford","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.transproceed.2013.10.040","article-title":"Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials","volume":"46","author":"YM Liu","year":"2014","journal-title":"Transplantation proceedings"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14656566.2014.903923","article-title":"Pharmacological management of polycystic kidney disease","volume":"15","author":"RP Wuthrich","year":"2014","journal-title":"Expert opinion on pharmacotherapy"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1053\/j.gastro.2011.04.030","article-title":"Polycystic liver diseases: congenital disorders of cholangiocyte signaling","volume":"140","author":"M Strazzabosco","year":"2011","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial","volume":"59","author":"M Chrispijn","year":"2013","journal-title":"Journal of hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"ra67","DOI":"10.1126\/scisignal.2001083","article-title":"Synthetic lethal screen of an EGFR-centered network to improve targeted therapies","volume":"3","author":"I Astsaturov","year":"2010","journal-title":"Sci Signal"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3374","article-title":"Harnessing synthetic lethal interactions in anticancer drug discovery","volume":"10","author":"DA Chan","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0272-6386(12)80507-5","article-title":"Polycystic kidney disease: neoplasia in disguise","volume":"15","author":"JJ Grantham","year":"1990","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise","volume":"74","author":"DA Proia","year":"2014","journal-title":"Cancer research"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"12786","DOI":"10.1073\/pnas.1301904110","article-title":"Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease","volume":"110","author":"T Seeger-Nukpezah","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm1675","article-title":"A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1","volume":"13","author":"K Piontek","year":"2007","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1097\/01.ASN.0000144204.01352.86","article-title":"A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo","volume":"15","author":"KB Piontek","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Acquaviva J, He S, Sang J, Smith DL, Sequeira M, <etal>et al<\/etal>. (2014) mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of Heat Shock Protein Synthesis. Molecular cancer research: MCR.","DOI":"10.1158\/1541-7786.MCR-13-0605"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Liu H, Xiao F, Serebriiskii IG, O&apos;Brien SW, Maglaty MA, <etal>et al<\/etal>. (2013) Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research.","DOI":"10.1158\/1078-0432.CCR-13-1115"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1078-0432.CCR-13-2166","article-title":"Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer","volume":"20","author":"DA Proia","year":"2014","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref26","first-page":"18s","article-title":"A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)","volume":"33","author":"S Ramalingam","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"G Walz","year":"2010","journal-title":"The New England journal of medicine"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T22:04:51Z","timestamp":1650751491000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114403"}},"subtitle":[],"editor":[{"given":"Guo-Chang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,4]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114403","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,4]]}}}